Тapгетная терапия после прогрессирования HER2-позитивного рака молочной железы


Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В., Чубенко В.А., Брежнев Н.В., Моисеенко Ф.В., Латипова Д.Х., Гершанович М.Л.

ФГБУ “НИИ онкологии им. Н.Н. Петрова” Минздравсоцразвития РФ, Санкт-Петербург. СПбГМУ им. акад. И.П. Павлова, Санкт-Петербург.
Обсуждается проблема дальнейшего применения таргетной терапии на основе трастузумаба у больных раком молочной железы (РМЖ) с гиперэкспрессией HER2, получающих такое лечение, у которых наступил рецидив или наблюдается прогрессирование процесса. Представленный в обзоре анализ многочисленных исследований показал, что продолжение при прогрессировании терапии трастузумабом и замена комбинаторного препарата достоверно улучшают результаты лечения РМЖ с гиперэкспрессией HER2. Эта концепция легла в основу рекомендаций NCCN по химиотерапии HER2-позитивного диссеминированного РМЖ в 2009 г., которые с тех пор не претерпели существенных изменений.

Литература


1. Cемиглазов В.Ф., Семиглазов В.В. Значение Герцептина в таргетной адъювантной терапии рака молочной железы // Фарматека, 2007. № 18 (152). С. 8–11.


2. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063–10.


3. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225.


4. Del Bianco S, Rondinelli R. Trastuzumabcontaining therapies: activity beyond disease progression in m.b.c. – a pivotal experience. Proc Am Soc Clin Oncol 2006;24:abstr.10788.


5. Morabito A, Longo R, Gattuso D, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncology Reports 2006;16:393–98.


6. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853–58.


7. Bachelot T, Mauriac L, Delcambre C, et al. Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with her2-positive metastatic breast cancer beyond disease progression. Proc Am Soc Clin Oncol 2007;25:abstr.1094.


8. Modi S, Stopeck A, Kinden H, et al. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with her2-positive trastuzumabrefractory metastatic breast cancer (mbc): phase 2 trial. Breast Cancer Res Treat 2007;106(1):abstr.6066.


9. Von Minckwitz G, Du bois A, Schmidt M, et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 2009;27:1999–2006.


10. Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. In: 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(15):abstr.1004.


11. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138–44.


12. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124–30.


13. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120–25.


14. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004;5: 52–8;59–62.


15. Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005;6:325–29.


16. Bartsch R, Wenzel C, Hussian D, et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 2006;6:63.


17. TokajukP, Czartoryska-ArlukowiczB, WojtukiewiczMZ, etal. Continuation of trastuzumabbased therapy beyond disease progression in metastatic breast cancer patients — a retrospective one center analysis. Eur J Cancer 2008;7(6):221:abstr.581.


18. Metro G, Mottolese M, Di Cosimo S, et al. Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). J Clin Oncol 2007;25:1066.


19. Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol 2007;18(6):11–15.


20. Cancello G, Montagna E, D’Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008;10:60.


21. Fabi A, Metro G, Ferretti G, et al. Do HER-2 positivemetastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? Amono-institutional experience and systematic review of observational studies. Breast 2008;7:499–505.


22. Montemurro F, Faggiuolo R, Redana S, et al. Continuation of trastuzumab beyond disease progression [letter]. J Clin Oncol 2005; 23:2866–68.


23. Antoine EC, Extra JM, Vincent-Salomon A, et al. Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: Results from the Hermine cohort study [abstract 2099]. Eur J Cancer 2007;43( 5):213.


24. Extra J-M, Antoine EC, Vincent-Salomon, et al. Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study. Oncologist 2010;15:799–809.


25. Stemmler HJ, Kahlert S, Siekiera W, et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005;28:582–86.


26. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumabbased therapy. Oncologist 2006;11:318–24.


27. Jackisch C, Eustermann H, Schoenegg W, et al. Clinical use of trastuzumab (Herceptin) in metastatic breast cancer (MBC) in Germany from 2001 to 2006. Breast Cancer Res Treat 2007;106(1):186, abstr.4059.


28. Campiglio M, Bufalino R, Sandri M, et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011;128(1):147–54.


29. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era [letter]. J Clin Oncol 2005;23:2114–16.


30. Pinder M, Chang HY, Broglio KM, et al. Trastuzumab treatment and brain metastases in HER2-positive metastatic breast cancer. In Poster 1018 Presented at the 43rd ASCO Annual Meeting, Chicago, IL, 1–5 June 2007;abstr.1018.


31. Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311–17.


32. Church DN, Modgil R, Guglani S, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008;31:250–54.


33. Brufsky AM, Mayer M, Rugo HS, et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clin Cancer Res 2011;17(14):4834–43.


34. Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19:1242–8.


35. Nam B-H, Kim SY, Han H-S et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:20.


36. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2positive metastatic breast cancer. Ann Oncol 2009;20:56–62.


37. Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010;21:942–48.


38. Vukelja S, Rugo H, Vogel S, et al. A phase II of trastuzumab-DM1, a first-class HER2 antibodydrug conjugate, in patients with HER2+ metastatic breast cancer. Cancer Res 2009;69:71.


Похожие статьи


Бионика Медиа